FDA Approves L-GLUTAMINE — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals received FDA approval for its oral L-Glutamine generic on May 26, 2026, positioning the company to compete in a high-volume therapeutic market. The launch is expected to exert downward pressure on prices and erode market share held by current brand-name leaders.